Cinda Bio announced that its stock (01801.HK) was included in the Hang Seng China Enterprise Index

The Hang Seng China Enterprises Index, as one of the broadly influential indexes in Hong Kong and even the international stock market, includes 50 Hong Kong-listed Chinese companies with leading market capitalization and trading volume

Executive Director Cinda biopharmaceutical group, Xi Hao, Chief Financial Officer, said: " We are very pleased that following last year's Hang Seng Composite Index and Hong Kong stocks through , but also became the first into the Hang Seng China Enterprises Index 18A innovative biopharmaceutical company

About Cinda Bio

"Starting from the letter, reaching the line", the development of high-quality biological drugs that the common people can afford is the ideal and goal of Cinda Bio

Since its establishment, the company has stood out among many biopharmaceutical companies with its innovative achievements and international operating model

Cinda Bio has established an internationally advanced high-end biopharmaceutical development and industrialization talent team, including many returned experts, and has cooperated with international partners such as Eli Lilly, Adimab, Incyte, MD Anderson Cancer Center, and Hanmi of South Korea.

Forward-looking statement

The information published in this press release may contain certain forward-looking statements

These forward-looking statements are based on the current views, assumptions, expectations, estimates, forecasts and understandings of the company’s management regarding future affairs at the time the statement was made

The company, the directors of the company, and employee agents shall not undertake (a) any obligation to correct or update any forward-looking statements contained in this website; and (b) if any forward-looking statements cannot be realized or become incorrect.